

Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a *Plasmodium falciparum* controlled human infection

Authors:

Jane Achan^{*1}, Isaie Reuling^{*2}, Xi Zen Yap², Edgard Dabira¹, Abdullahi Ahmad¹, Momodou Cox¹, Davis Nwakanma¹, Kevin Tetteh³, Lindsey Wu³, Guido J H Bastiaens², Yonas Abebe⁴, Anita Manoj⁴, Harparkash Kaur³, Kazutoyo Miura⁵, Carole Long⁵, Peter F Billingsley⁴, B. Kim Lee Sim⁴, Stephen L Hoffman⁴, Chris Drakeley³, Teun Bousema^{#2}, Umberto D'Alessandro^{#1}

^{*#}Equal contributors

Affiliations:

¹Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine, P.O Box 273, Banjul, The Gambia;

²Department of Medical Microbiology, Radboud university medical center, Geert Grooteplein 28, Microbiology 268, 6500 HB Nijmegen, The Netherlands; ³Department of Immunology and Infection, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.

⁴Sanaria Inc, Rockville, Maryland, United States of America, ⁵Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Corresponding Author: Dr Achan Jane, MRC Unit The Gambia at London School of Hygiene and Tropical Medicine, P.O. Box 273, Banjul, The Gambia; Email: jachan@mrc.gm. Tel: +2204495442

Summary

In this controlled human malaria infection study with PfSPZ Challenge, individuals with serological evidence of higher recent and cumulative malaria exposure had a longer prepatent period, lower mean parasite density at the time of treatment and fewer symptoms of malaria.

ABSTRACT

Background

We assessed the impact of exposure to *P. falciparum* on parasite kinetics, clinical symptoms, and functional immunity after controlled human malaria infection (CHMI) in two cohorts with different levels of previous malarial exposure.

Methods

Nine adult males with high (sero-high) and ten with low (sero-low) previous exposure received 3200 PfSPZ of PfSPZ Challenge by direct venous inoculation and were followed for 35 days for parasitemia by thick blood smear (TBS) and quantitative polymerase chain reaction (qPCR). End points were time to parasitemia, adverse events and immune responses.

Results

Ten of Ten (100%) volunteers in the sero-low and 7 of 9 (77.8%) in the sero-high group developed parasitemia detected by TBS in the first 28 days ($p = 0.125$). The median time to parasitemia was significantly shorter in the sero-low group [9 days (7.5-11.0) vs. 11.3 days (7.5-18.0), log rank test, $p=0.005$]. Antibody recognition of sporozoites was significantly higher in the sero-high (median 17.93 AU, IQR 12.95-24) than the sero-low volunteers (median 10.54 AU, IQR 8.36-12.12); $p=0.006$. Presence of blood-stage antibodies was also significantly higher ($p=0.0003$) in the sero-high group (median 50.98 AU, IQR 22.46-65.07) than in the sero-low group (median 3.16 AU, IQR 2.43-8.71). Growth inhibitory activity (GIA) was significantly higher in the sero-high (median 21.8%, IQR 8.15-29.65) than in the sero-low (median 8.3%, IQR 5.6-10.23) ($p=0.025$).

Conclusion

CHMI was safe and well tolerated in this population. Individuals with serological evidence of higher malaria exposure were able to better control infection and had higher parasite growth inhibitory activity.

Key words: malaria exposure, parasite kinetics, clinical outcomes, functional antibodies, controlled human malaria infection

BACKGROUND

Naturally acquired immunity against malaria parasites, which limits high-density parasitemia and severe disease, develops after repeated exposure, and more rapidly in high than in low transmission areas [1, 2]. This immunity is thought to be primarily mediated by anti-blood stage antibodies, which reduce parasite multiplication and cytoadherence of infected erythrocytes to endothelial cells [3]. In contrast, there is limited evidence for immunological responses preventing blood stage infection by neutralizing sporozoites and liver-stage parasites [4, 5].

Over the past two decades malaria control measures have led to substantial reductions in malaria burden [6], with several endemic countries transitioning from high-to-low malaria transmission [7, 8]. Decreased malaria exposure leads to increased susceptibility to infection and severe disease [9, 10], and is associated with decreased levels of antibodies to blood-stage antigens [11-13].

Controlled human malaria infection (CHMI) of healthy volunteers by exposure to the bites of infected, laboratory-reared *Anopheles* mosquitoes or inoculation of infected erythrocytes has been used for nearly 100 years to investigate malaria pathophysiology and immunology and efficacy of vaccines and drugs [14, 15]. During the last decade CHMI studies have been expanded in the US and Europe and increasingly performed in Africa using injectable, aseptic, purified, cryopreserved, vialled *Plasmodium falciparum* sporozoites (PfSPZ, Sanaria® PfSPZ Challenge)[5, 16-20], including assessment of innate resistance [5], naturally acquired immunity, and pre-erythrocytic and asexual erythrocytic stage vaccines [20, 21]. In this study we assessed how exposure to *P. falciparum*, as measured by serology to six pre-defined antigens, affected parasite kinetics, clinical symptoms, and functional immunity after CHMI by direct venous

inoculation (DVI) of PfSPZ Challenge [16, 17] in Gambian adult males with markedly different levels of previous malarial exposure.

METHODS

Study Design and participants

This was an open-label, non-randomized clinical trial, conducted at the Medical Research Council Unit The Gambia (MRCG). Healthy male participants aged 18–35 years were recruited between 13th and 23rd March 2018. Volunteers were preferentially recruited from tertiary learning institutions and provided written informed consent before screening. Eligible volunteers had normal haematological and biochemical tests and no abnormalities by electrocardiogram. Participants had to be *P. falciparum* negative by molecular methods on two occasions, at recruitment and just before DVI. Previous individual *P. falciparum* exposure was assessed using serologic responses to a panel of *P. falciparum* antigens using a Luminex platform [22]. These included responses associated with cumulative exposure, namely apical membrane antigen-1 (AMA-1), merozoite surface protein1.19 (MSP1.19) and glutamate-rich protein (GLURP.R2) [23], and responses associated with malaria infection in the past 6 months, namely reticulocyte-binding protein homologue (Rh2.2030), gametocyte exported protein (GEXP18) and Early transcribed membrane protein (Etramp5.Ag1) [24]. A complete description of the eligibility criteria is provided in Supplementary Appendix 1. The study received approval from the Scientific Coordinating Committee of MRCG, the Gambia Government/MRCG Joint Ethics Committee, and the London School of Hygiene and Tropical Medicine (LSHTM) Research and Ethics committee and was conducted according to the International Conference on

Harmonization – Good Clinical Practice (ICH-GCP) guidelines and registered with ClinicalTrials.gov, Identifier: NCT03496454.

Study Objectives

The primary objectives were to assess the feasibility of the CHMI model in The Gambia and determine the parasite kinetics in naturally exposed Gambian adults after PfSPZ Challenge administration. Secondary objectives were to analyse humoral and cellular immune responses and their association with time to patency and parasite density at time of first detection, and to assess frequency, incidence, nature and magnitude of adverse events.

PfSPZ Challenge

Sanaria® PfSPZ Challenge is composed of aseptic, purified, vialled, cryopreserved, fully infectious NF54 PfSPZ isolated from *Anopheles stephensi* mosquitoes [16, 18, 25]. PfSPZ Challenge was supplied by Sanaria Inc. as 20µL cyrovials containing 15,000 PfSPZ and stored in liquid nitrogen vapor phase at -150° to -196°C [25]. For this study, only one lot of PfSPZ manufactured on 30th April 2015 was used. The potency (capacity to invade and fully develop in cultured human hepatocytes (HC-04)) and viability (sporozoite membrane integrity) of this lot were tested as detailed in Supplementary Appendix 2.

Study Procedures

All screened volunteers were ranked by the cumulative quartile score of the mean fluorescent intensities of the six pre-defined antigens [24]. Volunteers with the highest and lowest scores, were assigned to the sero-high and sero-low groups, respectively. This classification resulted in significantly higher responses to all individual antigens reflected by mean fluorescent intensities of cumulative and recent exposure markers that were 4-13-fold and 3-5-fold higher respectively in the sero-high group (Supplementary Appendix 3). Whilst populations were defined based on a

cumulative quartile score for all antigens combined, recognition was also statistically significantly higher for the high exposure population for each of the 6 individual antigens ($p < 0.014$); (Figure 1). All volunteers received PfSPZ Challenge (3.2×10^3 PfSPZ in 0.5 mL) by DVI through a 25-gauge needle performed on a single day (29th March 2018) following Sanaria's standard operating procedures. After injection, participants were observed for 1 hour and subsequently closely monitored on an outpatient basis, with regular visits to the study clinic. Participants were instructed to register their daily symptoms in a study diary, measure temperature twice daily and contact the clinical investigators when any symptoms occurred. From day 5 post-injection onwards, participants were seen twice daily until day 15, and daily until day 28 or day of treatment. At each follow-up visit, temperature was taken, adverse events (AEs) recorded, and blood samples collected; physical examination was done on indication. Participants had a mobile phone by which they could be contacted. As an additional safety precaution, participants stayed in a hostel close to the study clinic from the day of infection until 3 days after treatment. The following signs and symptoms were solicited at all visits: fever, headache, malaise, fatigue, dizziness, myalgia, arthralgia, nausea, vomiting, chills, diarrhoea, abdominal pain, chest pain, palpitations and shortness of breath [26]. AEs were reported as mild (grade 1, easily tolerated), moderate (grade 2, interfered with normal activity), or severe (grade 3, prevented normal activity); for fever, as grade 1 (>37.5 °C to 38.0 °C), grade 2 (38.1 °C to 39.0 °C), or grade 3 (>39.0 °C). Laboratory values were graded using the DAIDS Table for Grading the Severity of Adult and Paediatric Adverse Events Version 2.1 March 2017.

If a thick blood smear (TBS) was positive with any parasitaemia, with or without signs and symptoms of malaria, treatment with artemether-lumefantrine was started immediately. Participants who did not develop parasitaemia by day 28 received artemether-lumefantrine on

that day. Treatment was directly observed, and all participants were seen at day 35 for an end of study visit.

Blood sampling and laboratory assessments

Screening for parasitaemia by microscopic examination of TBS and quantitative polymerase chain reaction (qPCR) was done twice daily from days 5 to 15 and daily from days 16 to 28. A complete blood count was done the day prior to PfSPZ Challenge injection, every three days between days 5-28, just before treatment and thereafter daily for the following three days and at day 35. Blood biochemistry was performed one day before PfSPZ Challenge injection, two days after treatment and at day 35. To check if volunteers had self-medicated with artemether-lumefantrine, lumefantrine levels were measured at baseline by high performance liquid chromatography with photodiode array detection [27]. Peripheral blood mononuclear cells were collected for immunological studies one day before PfSPZ Challenge injection and at day 35. Malaria infection was defined as asexual parasites in peripheral blood by TBS during the study and by qPCR retrospectively. The prepatent period was defined as the time between PfSPZ Challenge injection and first positive qPCR. TBS were performed according to an internationally harmonized protocol for thick smears in CHMI studies [28]. qPCR was done retrospectively using established methodologies [29] and considered positive at a parasite threshold of ≥ 5 parasites per mL.

Immunological assays

Assessment of sporozoite invasion inhibition by volunteer serum samples was done as described previously [30, 31] and in Supplementary Appendix 4. Antibody levels in citrate plasma from volunteers at baseline were measured by enzyme-linked immunosorbent assay (ELISA) to NF54

sporozoite or schizont extract. Growth inhibition was determined by invasion/growth inhibition assays (GIA) as described in Supplementary Appendix 4.

Sample size estimation and statistical analysis

Sample size calculation was based on the difference in prepatent period between groups. Assuming a mean time to qPCR positivity of 7.1 days (SD 0.8 days) [32], it was estimated that 15 participants per cohort would be sufficient to detect a 1-day longer time to first detection of parasites by qPCR in the high exposure group (8.1 days), with 90% power and alpha of 0.05. Due to low numbers of participants presenting for screening and volunteers not meeting eligibility criteria just before study start, only 19 volunteers were enrolled. Prepatent period and parasite density at first detection by qPCR were compared between groups using the log-rank test. For the immunological analyses, differences were assessed by comparing mean values between groups or time points using either a two-tailed Student's t-test or non-parametric equivalents. Time to patency and parasite density at first detection of infection were associated with immune responses.

RESULTS

Study population

Eighty-four volunteers were screened; of these, 8 were qPCR positive during screening. Nineteen volunteers at the extremes of the immunological spectrum (Supplementary Appendix 3) were enrolled into the study; 9 in the sero-high- and 10 in the sero-low group (Supplementary Appendix 5). Baseline characteristics are shown in Table 1. Most of the volunteers resided in the

West Coast region, an area previously reported to have low transmission compared to the other regions [33]. However, malaria transmission in The Gambia is highly heterogenous with both high- and low-exposed individuals in all regions. Volunteers in the sero-high group were older than those in the sero-low group; mean age 25.7 years (SD 3.3) vs. 22.6 years (SD 2.3) respectively, $p = 0.028$.

Parasite kinetics and clinical malaria

Seventeen of the 19 volunteers (89%) developed parasitemia detected by microscopy in the first 28 days of follow up: all individuals in the sero-low group (100%; 10/10) and 7 (77.8%; 7/9) in the sero-high group ($p = 0.125$), Table 2. One of the two volunteers who remained microscopy negative was qPCR positive at day 18 (Figure 2A and 2B). All volunteers reported no prior or current use of antimalarial drugs and none had measurable concentrations of lumefantrine at baseline. Median prepatent period was significantly shorter in the sero-low than in the sero-high group [9.0 days (SD 1.6) vs. 11.0 days (SD 6.3), log rank test, $p=0.005$] (Table 2, Figure 2B). Parasite density by qPCR on day of treatment was significantly higher in the sero-low than in the sero-high group, $p = 0.01$ (Figure 2C). Individual level parasite kinetics showed faster parasite multiplication in the sero-low group (Figure 3). Parasite multiplication rates (PMR_{48}) were calculated for all available 48-hour intervals following first detection of parasites by qPCR until treatment. Median PMR_{48} were non-significantly higher in the sero-low group ($p=0.143$) and were negatively associated with antibody titres against asexual parasite lysate ($r = -0.5074$, $p=0.0376$), (Supplementary Appendix 6).

Participants in the sero-low group had a significantly higher probability of having clinical malaria symptoms (90.0%, 9/10) than those in the sero-high (33%, 3/9), log rank $p = 0.0008$ (Table 2, Figure 4).

Safety and tolerability of PfSPZ Challenge

There were minimal AEs in the first 7 days after PfSPZ Challenge. Fourteen volunteers, 5 in the sero-high (55.6%) and 9 in the sero-low (90.0%) group experienced 82 AEs, including hematological and biochemistry abnormalities, that were possibly or probably related to malaria (Table 3). Seventy of the 82 (85.4%) AEs occurred in the sero-low, while only 12 (14.6%) occurred in the sero-high group ($p < 0.0001$). Most AEs (89.0%, 73/82) were mild to moderate and occurred around the time parasitemia became detectable by TBS. Moderate and severe AEs were only observed in the sero-low group (Table 3, Figure 4). Headache was the most frequently reported AE in both the sero-high (25%, 3/12) and sero-low (20%, 14/70) groups. Fever was only observed in the sero-low group (5/70, 7.1%), (Table 3). Of the 20 hematological and biochemistry abnormalities recorded, 75% (15/20) were in the sero-low and 25.0% (5/20) were in the sero-high group, $p = 0.002$. No serious AEs or cardiac AEs were reported, and all AEs had resolved by day 35.

Humoral and functional immunity

Antibody recognition of sporozoites by sporozoite-binding ELISA was significantly higher in plasma of sero-high (median 17.93 AU, IQR 12.95-24) compared to the sero-low volunteers (median 10.54 AU, IQR 8.36-12.12); ($p = 0.006$; Figure 5A). However, the groups did not differ in their ability to block sporozoite invasion of HC04 hepatocytes, (sero-high: median 88.26% invasion, IQR 83.52-100.1%; sero-low: 91.74% invasion, IQR 90.54-103, $p = 0.18$); ($p = 0.18$); (Figure 5B). Invasion was indexed as a percentage relative to invasion in the presence of non-immune serum from naïve donors, where 100% meant no invasion inhibition. The presence of blood-stage antibodies, determined by schizont extract was also significantly higher ($p = 0.0003$) in the sero-high group (median 50.98 AU, IQR 22.46-65.07; Figure 5C) than in the sero-low

group (median 3.16 AU, IQR 2.43-8.71). We observed indications for functional differences in blood-stage immune responses, with significantly higher GIA in the sero-high (median 21.8%, IQR 8.15-29.65) than in the sero-low (median 8.3%, IQR 5.6-10.23) ($p=0.025$; Figure 5D). Length of prepatent period correlated positively with sporozoite-binding antibody titres ($r=0.64$, $p=0.003$), blood-stage antibody titres ($r=0.48$, $p=0.036$) and blood-stage GIA activity ($r=0.65$, $p=0.003$) but not with sporozoite invasion inhibition ($r= -0.29$, $p=0.236$). For individual antibody responses, Rh2.2030 ($r = 0.5357$, $p=0.018$) and AMA-1 ($r = 0.4959$, $p=0.031$) were the most predictive of prepatent period (Supplementary Appendix 7). Significant correlation was also seen between the different immunological responses (Supplementary Appendix 8).

DISCUSSION

This study demonstrated the feasibility and successful implementation of CHMI with PfSPZ Challenge in The Gambia, increasing the capacity of conducting such studies in endemic areas: CHMI with PfSPZ Challenge has now been done in 6 African countries [5, 18-21]. A study in Gabon with PfSPZ Challenge reported that previous exposure to *P. falciparum* and sickle cell trait both impacted the rate of blood stage infection, prepatent period, and clinical manifestations of malaria [5]. Whilst previous studies in Kenya also associated immune responses to parasite kinetics among CHMI volunteers [34], ours is the first assessment of the effect of previous exposure to *P. falciparum* as measured by a pre-defined serology panel of six antigens on parasite kinetics, clinical symptoms and functional immune responses. Individuals with serological evidence of higher recent and cumulative malaria exposure had a longer prepatent period, lower mean parasite density and fewer symptoms of malaria. Whereas there was considerable variability in individual responses, the pre-screening panel used to define exposure

in this population correlated directly with clinical outcomes [22]. Using functional assays for pre-erythrocytic immunity and blood-stage immunity, this study also sheds light on the mechanisms underlying these differences. Anti-sporozoite responses were higher in highly exposed individuals but did not translate into responses preventing liver-stage infection *in vitro* whilst antibody responses controlling blood-stage parasite multiplication *in vitro* were markedly stronger in this group.

Understanding the impact of declining malaria exposure on malaria immunity is highly relevant in the context of wide-scale and often pronounced reductions in malaria burden in African and non-African settings [35, 36]. More direct methods for assessing immunity are needed to quantify the clinical consequences of declined exposure. Whilst we directly defined our cohorts based on serological markers that have been presented as indicators of recent and cumulative exposure [24, 37], several previous studies have indirectly determined malaria exposure based on self-reported clinical history of malaria episodes and long-term residence in malaria endemic areas [5, 23] or by measuring responses to whole parasite lysate and the blood stage antigen MSP-2 with a very long half-life [38]. In line with our findings, these studies observed a lower likelihood of parasite positivity post-CHMI in the highly exposed group [5, 23, 38]. Lell and colleagues postulated that mechanisms for the control of parasitemia included a combination of adaptive immune mechanisms such as prevention of hepatocyte infection, elimination of infected liver cells by T-cell mediated cytotoxicity or immune mediators and highly effective clearance of the first generation of merozoites leaving infected hepatocytes [5]. Our study directly examined differences in functional pre-erythrocytic and blood-stage immunity using established methodologies. Though we found no evidence for differences in inhibition of sporozoite invasion, we observed stronger parasite growth inhibition in the sero-high cohort. Since

volunteers were selected based on distinct immune profiles, our functional immune parameters must be interpreted with caution given challenges in disentangling functional immune responses from markers of exposure [39]. The single volunteer who remained parasite-negative by qPCR had median levels of pre-erythrocytic antibodies (17.93 AU), moderate HC04 invasion (104.13%; mean 95.41% invasion), very low levels of asexual antibodies (5.98 AU; mean 47.42 AU), and average GIA (23% inhibition; mean 21.94%). The striking difference in growth inhibition in our two cohorts suggests that functional blood-stage antibodies contributed significantly to the differences in clinical symptoms and parasite kinetics. There was a weak, negative correlation ($r = -0.4474$, $p = 0.0548$) between levels of sporozoite-binding antibodies and functional invasion-blocking activity, suggesting a minor invasion-blocking role for naturally acquired antibodies. Sporozoite-targeting antibodies in this study may be markers of exposure only or may enhance cellular immunity but lack direct invasion-blocking activity.

The systemic and laboratory AEs observed were consistent with uncomplicated malaria, with most AEs recorded at the time of positive microscopy. Severe symptoms, including chills, fatigue, malaise and headache reported in 3 sero-low volunteers were also consistent with uncomplicated malaria and resolved within 48 hours post-treatment. Two sero-low volunteers had grade 3 reductions in total lymphocyte count considered related to malaria and resolved by day 4 of malaria treatment. Similar declines have been reported previously [40]. This study does not allow us to extrapolate findings to other populations.

In summary, CHMI was safe and well tolerated in this population and the manifestations of malaria, although significantly different between the two exposure groups, were consistent with previous CHMI studies. Volunteers with high previous exposure to malaria infection were

able to better control the infection as shown by the significantly lower parasite densities, less severe symptoms and a lower incidence of symptoms associated with parasitemia.

Contributors

JA, IJR, GB, TB, CD, RWS and UD, designed the trial, which was performed by JA, IJR, ED and AA. PfSPZ was generated and prepared by AY for the clinical trial. Immunological assays were performed by XZY and MC. JA, IJR, GB, TB, RWS and UD provided regulatory and project support during the study. JA, IJR, XZY, TB, CD, RWS, UD analyzed and interpreted the data and results. JA and IJR wrote the original draft manuscript, which was critically reviewed and approved by all authors.

Acknowledgements

First and foremost, we thank the study volunteers who participated in this trial. We also thank the staff from the MRCG at LSHTM including Luntang Sanneh, Lamin Drammeh, Abdoulie Sowe, Kalilu Kanyi, Isatou Mahmoud, Matarr Ceesay and Pitty Nasso and from Radboudumc including Kevin Bos and Annemiek De Boer. Special thanks to Alpha Bah, Kodou Lette, Karen Forrest and Nuredin Ibrahim Mohammed for their assistance and support during the trial. We thank the following individuals: Simon Corea, Sukai Ceesay, Bola Lawal and Khadijatou Jawneh for all the safety laboratory assessments and for reading many microscopy smears. We also acknowledge the following individuals for supplying antigens; Linda Reiling and James Beeson for Rh2.2030, Susheel K Singh for GLURP.R2 and Draper S.J. for Rh5.1 Etramp5.Ag1. We thank the Sanaria Manufacturing team for production of PfSPZ Challenge, and to Sanaria's Quality, Regulatory, Pharmaceutical Operations and Clinical teams for their support.

Funding

This work was part of the WANETAM II project which is supported by the European and Developing Countries Clinical Trials Partnership (EDCTP) and The Netherlands Organization

for Scientific Research (VIDI grant to TB with project number 016.158.306). TB is further supported by a fellowship from the European Research Council (ERC-2014-StG 639776). This work was also supported in part with Federal funds from the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health SBIR 2R44AI058375 (granted to SLH). The GIA work was supported by the United States Agency for International Development (USAID) and the Intramural Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases

Conflict of interests

Yonas Abebe, Anita Manoj, Kazutoyo Miura, Carole Long, Peter F Billingsley, B. Kim Lee Sim, and Stephen L Hoffman work for Sanaria Inc. Chris Drakely reports grants from Intellectual Ventures/ Global Good. Stephen L Hoffman and B. Kim Lee Sim have been issued a patent on purified PfSPZ. All other authors declare no competing interests.

REFERENCES

1. Fowkes, F.J., P. Boeuf, and J.G. Beeson, *Immunity to malaria in an era of declining malaria transmission*. Parasitology, 2016. **143**(2): p. 139-53.
2. Doolan, D.L., C. Dobano, and J.K. Baird, *Acquired immunity to malaria*. Clin Microbiol Rev, 2009. **22**(1): p. 13-36, Table of Contents.
3. Tran, T.M., et al., *An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection*. Clin Infect Dis, 2013. **57**(1): p. 40-7.
4. Hoffman, S.L., et al., *Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications*. Science, 1987. **237**(4815): p. 639-42.
5. Lell, B., et al., *Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon*. Am J Trop Med Hyg, 2018. **98**(2): p. 508-515.
6. Organisation, W.H. *World Malaria Report*. 2018; Available from: <https://www.who.int/malaria/publications/world-malaria-report-2018/en/>.
7. Kalayjian, B.C., et al., *Marked decline in malaria prevalence among pregnant women and their offspring from 1996 to 2010 on the south Kenyan Coast*. Am J Trop Med Hyg, 2013. **89**(6): p. 1129-34.
8. Snow, R.W., et al., *Changing Malaria Prevalence on the Kenyan Coast since 1974: Climate, Drugs and Vector Control*. PLoS One, 2015. **10**(6): p. e0128792.
9. Mogeni, P., et al., *Age, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational Study*. PLoS Med, 2016. **13**(6): p. e1002047.
10. Griffin, J.T., et al., *Gradual acquisition of immunity to severe malaria with increasing exposure*. Proc Biol Sci, 2015. **282**(1801): p. 20142657.
11. Migot, F., et al., *Human immune responses to the Plasmodium falciparum ring-infected erythrocyte surface antigen (Pf155/RESA) after a decrease in malaria transmission in Madagascar*. Am J Trop Med Hyg, 1993. **48**(3): p. 432-9.
12. Diop, F., et al., *Dramatic declines in seropositivity as determined with crude extracts of Plasmodium falciparum schizonts between 2000 and 2010 in Dielmo and Ndiop, Senegal*. Malar J, 2014. **13**: p. 83.
13. Wong, J., et al., *Serological markers for monitoring historical changes in malaria transmission intensity in a highly endemic region of Western Kenya, 1994-2009*. Malar J, 2014. **13**: p. 451.
14. Sauerwein, R.W., M. Roestenberg, and V.S. Moorthy, *Experimental human challenge infections can accelerate clinical malaria vaccine development*. Nat Rev Immunol, 2011. **11**(1): p. 57-64.
15. Staniscic, D.I., J.S. McCarthy, and M.F. Good, *Controlled Human Malaria Infection: Applications, Advances, and Challenges*. Infect Immun, 2018. **86**(1).
16. Mordmuller, B., et al., *Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres*. Malar J, 2015. **14**: p. 117.
17. Gomez-Perez, G.P., et al., *Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates*. Malar J, 2015. **14**: p. 306.

18. Shekalaghe, S., et al., *Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites*. Am J Trop Med Hyg, 2014. **91**(3): p. 471-480.
19. Hodgson, S.H., et al., *Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya*. Malar J, 2015. **14**: p. 182.
20. Jongo, S.A., et al., *Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults*. Am J Trop Med Hyg, 2018. **99**(2): p. 338-349.
21. Dejon-Agobe, J.C., et al., *Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2*. Clin Infect Dis, 2018.
22. Lindsey Wu, T.H., Isaac Ssewanyana, Tate Oulton, Catriona Patterson, Hristina Vasileva, Susheel Singh, Muna Affara, Julia Mwesigwa, Simon Correa, Mamadou Bah, Umberto D'Alessandro, Nuno Sepúlveda, Chris Drakeley, Kevin K A Tetteh, *Optimisation and standardisation of a multiplex immunoassay of diverse Plasmodium falciparum antigens to assess changes in malaria transmission using sero-epidemiology* Wellcome Open Research, 2019. **4**(26).
23. Obiero, J.M., et al., *Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection*. Infect Immun, 2015. **83**(5): p. 2185-96.
24. Helb, D.A., et al., *Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities*. Proc Natl Acad Sci U S A, 2015. **112**(32): p. E4438-47.
25. Hoffman, S.L., et al., *Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria*. Hum Vaccin, 2010. **6**(1): p. 97-106.
26. Walk, J., et al., *Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial*. BMC Med, 2017. **15**(1): p. 168.
27. Khalil, I.F., et al., *Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection*. J Pharm Biomed Anal, 2011. **54**(1): p. 168-72.
28. Laurens, M.B., et al., *A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines*. Vaccine, 2012. **30**(36): p. 5302-4.
29. Hermsen, C.C., et al., *Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR*. Mol Biochem Parasitol, 2001. **118**(2): p. 247-51.
30. Kaushansky, A., et al., *Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites*. Mol Biochem Parasitol, 2012. **183**(1): p. 100-3.
31. Behet, M.C., et al., *The complement system contributes to functional antibody-mediated responses induced by immunization with Plasmodium falciparum malaria sporozoites*. Infect Immun, 2018.
32. Bastiaens, G.J.H., et al., *Safety, Immunogenicity, and Protective Efficacy of Intradermal Immunization with Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites in Volunteers Under Chloroquine Prophylaxis: A Randomized Controlled Trial*. Am J Trop Med Hyg, 2016. **94**(3): p. 663-673.
33. Mwesigwa, J., et al., *Residual malaria transmission dynamics varies across The Gambia despite high coverage of control interventions*. PLoS One, 2017. **12**(11): p. e0187059.

34. Hodgson, S.H., et al., *Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection*. *Front Microbiol*, 2014. **5**: p. 686.
35. Snow, R.W. and K. Marsh, *New insights into the epidemiology of malaria relevant for disease control*. *Br Med Bull*, 1998. **54**(2): p. 293-309.
36. Rolfes, M.A., et al., *Development of clinical immunity to malaria in highland areas of low and unstable transmission*. *Am J Trop Med Hyg*, 2012. **87**(5): p. 806-12.
37. Drakeley, C.J., et al., *Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure*. *Proc Natl Acad Sci U S A*, 2005. **102**(14): p. 5108-13.
38. Abdi, A.I., et al., *Plasmodium falciparum malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure*. *BMC Infect Dis*, 2017. **17**(1): p. 585.
39. Kinyanjui, S.M., et al., *What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity*. *Malar J*, 2009. **8**: p. 242.
40. Reuling, I.J., et al., *A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model*. *Elife*, 2018. **7**.

Table 1. Demographic characteristics of volunteers enrolled in the Gambia controlled human malaria infection study

	High Exposure group	Low Exposure group	p-value
Number of participants (n)	9	10	0.752
Age in years (mean, SD)	25.7 (3.3)	22.6 (2.3)	0.028
Male gender: n (%)	9 (100%)	10 (100%)	-
Height in cm	177.0 (174.0-182.0)	177.0 (174.0-181.0)	0.968
Weight in Kg	62.8 (59.8-80.1)	64.8 (52.8-86.7)	0.490
BMI in Kg/m ²	21.0 (18-26)	20.7 (18-26)	0.936
Ethnicity: n (%)			
Mandika	2 (22.2)	7 (70.0)	0.043
Fula	5 (55.6)	1 (10.0)	0.038
Other	2 (22.2)	2 (20.0)	0.909
Residence: n (%)			
West coast region	7 (77.8)	7 (70.0)	0.707
Upper river region	2 (22.2)	0 (0.0)	0.125
Central river region	0 (0.0)	3 (30.0)	0.081

Median (range) for all continuous variables except where noted

Table 2: Parasitological and clinical outcomes following controlled human malaria infection

	High Exposure group N= 9.0	Low Exposure group N = 10.0	P value
Number of subjects positive by microscopy	7.0 (77.8%)	10.0 (100.0%)	0.125
Number of subjects positive by qPCR	8.0 (88.9%)	10.0 (100.0%)	0.292
Days to parasitemia by microscopy*	14.0 (6.6)	13.5 (1.5)	0.327
Days to parasitemia by qPCR*	11.0 (6.3)	9.0 (1.6)	0.016
Days from qPCR positivity to microscopy positivity*	3.0 (2.6)	5.0 (0.5)	0.156
Number of subjects who developed symptoms**	3.0 (33.3%)	9.0 (90.0%)	0.013

Peak parasite density during study (qPCR, parasites/mL) ***	3748.9 (50.6-71264.3)	49340.3 (5186.5-205850)	0.088
Area under the curve (AUC) of parasitemia until treatment (qPCR) (median (range)) ****	8035 (0-122054)	34504 (3404-120441)	0.173

*Median (standard deviation), **only possibly or probably related to study, ***Geometric mean (range), qPCR = quantitative polymerase chain reaction (≥ 5 parasites/mL), ****The area under the curve (AUC) represents the total parasite exposure over time until treatment (parasite load).

Table 3: Adverse events following controlled human malaria infection in the two exposure groups

	Sero-high group N= 9	Sero-low group N = 10
Number of participants with any adverse events (including laboratory abnormalities)	5.0 (55.6%)	9.0 (90.0%)
Number of participants with adverse events \geq grade 2	2.0 (22.2%)	8.0 (80.0%)
Grade 1 and 2 adverse events		
Total	12.0	61.0
Headache	3.0 (25.0%)	12.0 (19.7%)
Fever	0.0	5.0 (8.2%)
Chills	1.0 (8.3%)	4.0 (6.6%)
Fatigue/malaise	1.0 (8.3%)	8.0 (13.1%)
Myalgia	0.0	4.0 (6.6%)
Arthralgia	2.0 (16.7%)	1.0 (1.6%)
Anorexia	0.0	5.0 (8.2%)
Nausea	0.0	2.0 (3.3%)
Vomiting	0.0	1.0 (1.6%)
Abdominal pain	0.0	2.0 (3.3%)
Dizziness	0.0	3.0 (4.9%)
Diarrhoea	0.0	1.0 (1.6%)
Ribcage pain	0.0	1.0 (1.6%)
Low platelet count	1.0 (8.3%)	2.0 (3.3%)
Low lymphocyte count	1.0 (8.3%)	5.0 (8.2%)
Low absolute neutrophil count	1.0 (8.3%)	0.0
Elevated total bilirubin	0.0	2.0 (3.3%)
Elevated lactate dehydrogenase	0.0	1.0 (1.6%)
Elevated aspartate transaminase *	0.0	1.0 (1.6%)
Elevated Gamma-glutamyl transferase	1.0 (8.3%)	0.0
Elevated Sodium levels	1.0 (8.3%)	1.0 (1.6%)
Grade 3 adverse events		
Total	0.0	9.0
Headache	0.0	2.0 (22.2%)
Chills	0.0	2.0 (22.2%)
Fatigue/malaise	0.0	2.0 (22.2%)
Low lymphocyte count	0.0	3.0 (33.3%)

*No clinically significant elevations in alanine aminotransferase (ALT) were observed

Figure Legends

Figure 1: Antibody histogram plots for screened volunteers in the Gambia controlled human malaria infection study**

** Light colors are the sero-low group, dark colors are the sero- high group and grey colors are the other screened volunteers with intermediate immunological profile.

Figure 2. Comparison of parasite kinetics between the two exposure groups following controlled human malaria infection

Kaplan Meier curve for time from inoculation to parasitemia detected by thick blood smear (A) and qPCR (B). Differences in parasite density by qPCR at treatment (C) and peak parasitemia (D)

Figure 3. Individual level kinetics of parasitemia by qPCR following controlled human malaria infection

Figure 4. Differences in clinical outcomes following controlled human malaria infection in the two exposure groups[§]

[§] Shows proportion of participants without symptoms, number of AEs per participant and total number of AEs per group

Figure 5. Antibody-mediated responses to *P. falciparum* in high- and low-exposure groups

(A) The sero-high group had significantly higher ($p=0.006$) titres of antibodies to sporozoite antigens, expressed as arbitrary units (AU). **(B)** There were no significant differences between groups in their ability to block sporozoite invasion of HC04 hepatocytes. **(C)** Plasma from the sero-high group also had significantly higher ($p=0.0003$) levels of antibodies to asexual-stage antigens, also expressed as AU. **(D)** Purified IgG from the sero-high exposure group also had significantly higher growth inhibitory activity ($p=0.025$) against blood-stage 3D7 parasites.

Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5.

